Benjamin Arnold

Walk into COR Medical Ventures expecting a single product and you will leave confused. There isn't one. There are about a dozen.

Benjamin Arnold is the co-founder and CEO of COR Medical Ventures, a venture studio tucked into Solana Beach, just up the coast from San Diego. It is not a typical startup. Most founders pick a problem, build a thing, and spend a decade on it. Arnold built the machine that builds the things - a studio that takes a surgeon's frustration, or a corporation's orphaned patent, and runs it down the long, regulated road to a device that a hospital will actually buy.

The name is the tell. "COR" is shorthand for center of rotation, the engineering term for the fixed point around which a body turns. In an implant, it is the spot the mechanics resolve to. In Arnold's company, it is the role he plays: the still point at the middle of a dozen moving companies, each spinning on its own axis, all of them pulling from the same shared pool of regulatory, prototyping, and fundraising muscle.

That structure has three arms. A consulting practice that sells the hard-won know-how directly. A venture studio that co-founds and incubates new device companies. And a distribution operation that gets cleared products into the field. Put together, they cover nearly the entire distance between a clinical need scribbled on a notepad and a product on a sales rep's table.

Arnold's own job description is unglamorous and enormous: technology assessment and strategy on one side, internal operations and planning on the other. Translation - he decides which ideas are worth chasing, then makes sure the chasing actually happens.

Before he was assembling companies, Arnold was assembling implants. He holds both an undergraduate and a master's degree in engineering from Cornell University, and the resume that followed reads like a tour of the spine industry's most serious addresses.

He worked in product development at DePuy Spine, part of the Johnson & Johnson orthopedics empire. He led the Development Technology Team at NuVasive, the San Diego company that spent the 2000s and 2010s rewriting how spine surgery is done. And he consulted for Synthes Spine, the trauma-and-spine powerhouse later folded into J&J. Three of the biggest names in the field, all on one CV.

The throughline is volume. Over those years, Arnold led product development teams to more than 25 successful medical device launches. That number matters more than any single product, because in medical devices the failures vastly outnumber the launches. A device that clears the FDA, survives manufacturing scale-up, and reaches a patient has already beaten long odds. Doing it 25 times is less luck than method.

He has put his own name on the paperwork too. A 2018 FDA 510(k) filing, K181076, lists Benjamin Arnold as managing member of Responsive Arthroscopy LLC - the regulatory fine print that comes with actually shipping hardware rather than just advising on it.

The clearest way to understand Arnold is to look at what his studio is building. It does not read like a focused thesis. It reads like a medical trade show floor - which is the point. A studio spreads its risk across many shots rather than betting the house on one.

The conventional medical-device story is a tragedy waiting to happen. A surgeon has a brilliant idea. The surgeon raises money, builds a one-product company, and then spends years discovering that the idea was the easy part - that regulatory strategy, quality systems, prototyping, and manufacturing are each their own discipline, and that running out of money before clearance is the default outcome.

Arnold's answer is to pool the boring, expensive parts. The regulatory know-how, the prototyping shop, the quality systems, the fundraising relationships - these live at the center and get shared across every company in orbit. A surgeon-inventor walking in with a sketch does not have to build all of that from scratch. They plug into a hub that has done it 25 times before.

It is a quietly contrarian bet. Most venture money wants focus - one company, one product, one story. Arnold is wagering that in a field this technical and this regulated, breadth is the edge. The studio can run a Phase 3 drug/device trial and a handheld surgical robot and a wearable breast pump at the same time, because the constraint was never imagination. It was always execution. And execution, unlike inspiration, scales when you centralize it.

The proof points are accumulating. Several portfolio companies - Sail Fusion, Spine Innovation, Osheru - are already commercial or FDA-cleared. Others sit mid-pipeline with issued patents and defined regulatory paths. In 2024, COR put capital into Sail Fusion, the kind of follow-on move that signals a studio backing its own winners rather than just spinning out and walking away.